10.1021/bm400626w.s001
Tzu-Yu Liu
Tzu-Yu
Liu
Waleed
M. Hussein
Waleed
M.
Hussein
Zhongfan Jia
Zhongfan
Jia
Zyta M. Ziora
Zyta M.
Ziora
Nigel A. J. McMillan
Nigel
A. J. McMillan
Michael J. Monteiro
Michael J.
Monteiro
Istvan Toth
Istvan
Toth
Mariusz Skwarczynski
Mariusz
Skwarczynski
Self-Adjuvanting Polymer–Peptide Conjugates
As Therapeutic Vaccine Candidates against Cervical Cancer
American Chemical Society
2013
polymer
biomacromolecule
antigen
conjugate
peptide
protein
adjuvant
platform
Cervical CancerDendrimers
pathway
papillomaviru
HPV
vaccine candidate
Therapeutic Vaccine Candidates
physicochemical properties
Polymer
e.g
Herein
TC
immunization
tumor growth
Conjugate
2013-08-12 00:00:00
Journal contribution
https://acs.figshare.com/articles/journal_contribution/Self_Adjuvanting_Polymer_Peptide_Conjugates_As_Therapeutic_Vaccine_Candidates_against_Cervical_Cancer/2388541
Dendrimers are structurally well-defined,
synthetic polymers with
sizes and physicochemical properties often resembling those of biomacromolecules
(e.g., proteins). As a result, they are promising candidates for peptide-based
vaccine delivery platforms. Herein, we established a synthetic pathway
to conjugate a human papillomavirus (HPV) E7 protein-derived peptide
antigen to a star-polymer to create a macromolecular vaccine candidate
to treat HPV-related cancers. These conjugates were able to reduce
tumor growth and eradicate E7-expressing TC-1 tumors in mice after
a single immunization, without the help of any external adjuvant.